LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Search

BioMarin Pharmaceutical Inc

Gesloten

SectorGezondheidszorg

52.92 -0.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

53.1

Max

53.42

Belangrijke statistieken

By Trading Economics

Inkomsten

-457M

-31M

Verkoop

-49M

776M

K/W

Sectorgemiddelde

20.457

80.03

EPS

1.44

Winstmarge

-3.961

Werknemers

3,040

EBITDA

-324M

-5.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+60.82% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

111M

11B

Vorige openingsprijs

53.82

Vorige sluitingsprijs

52.92

Nieuwssentiment

By Acuity

67%

33%

333 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 dec 2025, 23:00 UTC

Acquisities, Fusies, Overnames

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5 dec 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Meta Platforms Buys AI-Device Maker Limitless

5 dec 2025, 19:39 UTC

Belangrijke Marktbewegers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec 2025, 19:17 UTC

Acquisities, Fusies, Overnames

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

7 dec 2025, 23:05 UTC

Marktinformatie

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7 dec 2025, 22:18 UTC

Marktinformatie

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6 dec 2025, 16:52 UTC

Acquisities, Fusies, Overnames

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dec 2025, 10:30 UTC

Acquisities, Fusies, Overnames

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dec 2025, 02:38 UTC

Acquisities, Fusies, Overnames

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec 2025, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

5 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec 2025, 21:36 UTC

Marktinformatie

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec 2025, 21:12 UTC

Marktinformatie

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec 2025, 21:03 UTC

Marktinformatie
Winsten

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec 2025, 21:01 UTC

Marktinformatie

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec 2025, 20:42 UTC

Acquisities, Fusies, Overnames

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec 2025, 20:01 UTC

Acquisities, Fusies, Overnames

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec 2025, 19:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 dec 2025, 19:44 UTC

Marktinformatie

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec 2025, 19:39 UTC

Marktinformatie

Silver Climbs to a New Record High -- Market Talk

5 dec 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:30 UTC

Marktinformatie

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec 2025, 18:28 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:24 UTC

Acquisities, Fusies, Overnames

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Peer Vergelijking

Prijswijziging

BioMarin Pharmaceutical Inc Prognose

Koersdoel

By TipRanks

60.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 85.88 USD  60.82%

Hoogste 120 USD

Laagste 55 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioMarin Pharmaceutical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

19 ratings

14

Buy

5

Hold

0

Sell

Technische score

By Trading Central

59.405 / 62.19Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

333 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat